AzTrials
AzTrials

EndometriosisNCT06215937

Quantitative Sensory Testing and Central Sensitization in Endometriosis

An observational study of Endometriosis and Pain, run by BC Women's Hospital & Health Centre at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Endometriosis is a gynecologic condition where there is growth of endometrial-like tissue outside the uterus, leading to severe pelvic pain. Despite conventional treatment, many patients experience persistent pelvic pain due to central sensitization (CS), where the central nervous system amplifies pain signals. Read more about this study

Who is it for?
Ages 19 to 49 years, women only
Conditions the study is for
Endometriosis, Pain
How many people
126 participants
Where
1 siteCanada
Study dates
1 May 2024to 30 Apr 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 49 years
  • Women only
  • Adult

Study population: Individuals who have a new or re-referral appointment at the BC Women's Centre for Pelvic Pain and Endometriosis and who consented to the EPPIC registry (H16-00264).

Who may be able to join

  • New or re-referral appointment at the BC Women's Centre for Pelvic Pain and Endometriosis.
  • Consented to be contacted for future research in the centre data registry (EPPIC NCT02911090; H16-00264).
  • Surgically confirmed endometriosis, current imaging diagnosis, or current clinically suspected endometriosis diagnosed at the new or re-referral appointment as coded in the registry.
  • 19 to 49 years old.
  • Willing and committed to completing six questionnaires about pain.
  • QST specific criteria
  • Willing and committed to QST testing.

Who cannot join

  • Currently pregnant or breastfeeding.
  • Post-menopausal.
  • Does not speak English - Patients who do not speak English will be excluded to maintain the safety and well-being of the patient, as not understanding the test and process may harm the patient and reduce the validity of the results. We do not have research funding for a translator. Additionally, patients who require a translator are not typically included in the data registry and therefore are unlikely to be in our sample.
  • QST specific criteria
  • Diabetes or neurological disease predisposing to neuropathic pain.
  • Previous laparotomy (i.e. large abdominal incision)
  • Physical trauma (ex., surgery, scaring) to heterotropic QST test site(s) (i.e. deltoid muscle in the shoulder, thenar eminence).

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • BC Women's Hospital + Health Centre

    Vancouver, British Columbia, V6H 2N9

Other trials in Canada

About this study

Endometriosis is a gynecologic condition where there is growth of endometrial-like tissue outside the uterus, leading to severe pelvic pain. Despite conventional treatment, many patients experience persistent pelvic pain due to central sensitization (CS), where the central nervous system amplifies pain signals. Quantitative Sensory Testing (QST) enables objective testing of CS. However, there are several patient-reported questionnaires that have shown promising potential as subjective proxies of CS.

Therefore, in this study, our objective is to validate six patient-reported questionnaires as measures of CS by comparing them to each other and determining whether each questionnaire correlates with QST thresholds.

Read the detailed description

Purpose: To validate the Central Sensitization Inventory (CSI), the Pain Sensitivity Questionnaire (PSQ), the Douleur Neuropathique 4 (DN4) questionnaire, the painDETECT (PD-Q) questionnaire, the Self Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) and the Fibromyalgia (FM) Survey Score (FSS) as subjective proxies for detecting CS in cases of endometriosis.

Justificaiton: There has yet to be a direct comparison among these six questionnaires in endometriosis. Further research is needed to explore the overlap and effectiveness of these measures in the context of endometriosis and CS. Moreover, these six questionnaires have not been validated with quantitative sensory testing (QST) in endometriosis.Quantitative Sensory testing (QST) is an objective assessment tool for measuring CS. It quantifies the dynamic, altered modulation of nociceptive signals and allows for the objective testing of somatosensory function and central sensitization by applying various stimuli (such as pressure, pinprick, temperature etc.) to different body regions and recording pain thresholds (Rolke et al., 2006). Therefore, in this study, our objective is to compare the six patient-reported questionnaires to each other, and determine whether each questionnaire correlates with QST thresholds.

Primary Objective: Validate the CSI/PSQ/DN4/PD-Q/S-LANSS/FSS questionnaires as proxies for detecting CS in cases of endometriosis.

  1. Examine the correlation between each questionnaire's scores with each other and the number of central sensitivity syndromes and other pelvic pain-related comorbidities (CSS) in patients with endometriosis.
  2. Examine the association between questionnaire scores and the baseline QST thresholds in patients with endometriosis.

Secondary Objectives: Examine how the questionnaires and QST thresholds, correlate with pain severities, quality-of-life measured using the Endometriosis Health Profile (EHP-30) scores, demographic variables, as well as examination and surgical phenotyping of endometriosis.

Hypothesis: Higher scores on the CSI/PSQ/DN4/PD-Q/S-LANSS/FSS questionnaires will be associated with lower QST thresholds (as well as an increased number of CSS and other pelvic pain-related conditions) indicating greater central sensitization) in people with endometriosis

Research Design: This study is a cross-sectional correlational study, where all data points will be collected from participants at one point in time. The data collection process will include the collection of scores on six pain questionnaires (i.e.CSI, PSQ, DN4, PD-Q, S-LANSS and FSS) and threshold data from QST. All participants will be asked to complete the questionnaires. Depending on QST eligibility, determined during the screening assessment, and informed consent, a subgroup of participants will be asked to complete additional QST to obtain threshold data. The data analyses will focus on examining the relationships between each questionnaire and, for participants undertaking both the questionnaires and QST, the relationship between QST thresholds and each questionnaire.

Independent variables: Scores from the following questionnaires:

  • CSI: CSI total score
  • PSQ: PSQ minor score (avg. of scores from items 3,6,7,10,11,12,14) and the PSQ total score (avg. of scores from items 1,2,3,4,6,7,8,10,11,12,14,15,16)
  • DN4: DN4 total score (sum of scores from items 1-7)
  • PD-Q: PD-Q total score (sum of 7 sensory questions)
  • S-LANSS: SLANSS total score
  • FSS: FSS total score (WPI+ SS= SS) Main Outcome Variables: QST thresholds for assessment of CS PPT: avg. of duplicated PPT (kPa) at each test site VDT: avg. of VDT (Hz) at each test site MPT: avg. of duplicated MPT (NmN) at each test site MDT: avg. pain intensity rating on a 0-100' numerical rating scale (NRS) at each site SR- Fucntion: avg. pain intensity rating on a 0-100' numerical rating scale (NRS) at each site WUR: avg. of 5 WUR measurements (NmN) CPT: avg. of duplicated CPT (℃) at each test site CDT: avg of CDT (℃) at each test site HPT: avg. of duplicated HPT (℃) at each test site WDT: avg. of WDT (℃) at each test site CPM: avg. cearly CPM-effect and late CPM-effecthange in HPT (pain intensity on NRS)

Analysis of Data:All statistical analysis will be conducted using R or IBM SPSS, statistical software that allows for advanced data analysis, modelling, and visualization. For the primary analysis, we will conduct correlation analysis (Pearsons or Spearman's correlation) to assess the correlation, strength and direction of the associations between each questionnaire with each other and with other pelvic pain comorbidities (CSS). We will also examine the correlation/association between scores on each questionnaire and baseline QST thresholds. We will also determine lower QST thresholds correlate with an increasing number of CSS. For our secondary analysis, summary statistics, bivariate testing, T-tests, Mann-Whitney U test or Kruskal-Wallis tests will be conducted to determine the association between questionnaires and QST thresholds, and with various socioeconomic, demographic and anatomical phenotyping factors (e.g., endometriosis Stage, anatomic subtypes, histological confirmation, coexisting adenomyosis). We will also conduct correlation analysis to determine the association between pain severities and scores on the EHP-30. Regression analyses may be done with adjustments will be made for potential confounders (e.g. age, endometriosis stage and hormone therapy). All findings will be considered statistically significant at a threshold of p < 0.05.

Conditions
Endometriosis, Pain
Being tested
No Intervention
Medical subject headings
Endometriosis, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No InterventionOther

    No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Central Sensitization

    Quantitative Sensory Testing thresholds for assessment of Central Sensitization

    Measured: Feb 1st 2023 - Jan 31st 2026

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jan 2024
  2. Study start1 May 2024
  3. Primary completion28 Feb 2026
  4. Study completion30 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
126 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06215937
Sponsor's protocol ID
H22-02631
Status last verified
Aug 2026
First submitted
11 Jan 2024
Last updated
2 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Endometriosis and Pain, run by BC Women's Hospital & Health Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Central Sensitization (time frame: Feb 1st 2023 - Jan 31st 2026). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in